Hydroxychloroquine-d5

Hydroxychloroquine-d5

• UNSPSC Description: Hydroxychloroquine-d5 is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].
• Target Antigen: Autophagy; Parasite; SARS-CoV; Toll-like Receptor (TLR)
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Autophagy;Immunology/Inflammation
• Applications: COVID-19-anti-virus
• Field of Research: Cancer
• Solubility: 10 mM in DMSO
• Smiles: CC(NC1=CC=NC2=C1C=CC(Cl)=C2)CCCN(CCO)C([2H])(C([2H])([2H])[2H])[2H].OC(C(O)=O)=O.OC(C(O)=O)=O
• Molecular Weight: 520.97
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.|[3]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar85(3):429-40.|[4]Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported